该话题已被锁定 - xxll2006 , 2013-03-16 22:18
如果您尚不清楚该话题被锁定的原因，请参考论坛规则以及本版公告或者联系本版版主

发帖
每发1个新帖
可以获得0.5个丁当奖励
回帖

【商业翻译—医师报约稿】Troxacitabine, Gemcitabine May Be Synergistic ...

只看楼主
页码直达：
直达末页

楼主

riset

丁香园荣誉版主

1楼

这个帖子发布于13年零46天前，其中的信息可能已发生改变或有所发展。

1.保证质量。
2.本周五中午12点前译者完成编译，周六中午12点之前校对者完成校对，周六晚上8点前译者根据校对的意见修正编译的文章。
3.翻译并非简单直译，格式见版内置顶的文摘编译格式：
http://www.dxy.cn/bbs/post/view?bid=116&id=8600034&sty=1&tpg=1&age=0
4.稿酬按医师报标准(根据质量分为ABC三等，评级由医师报编辑进行)。
5.为保证翻译质量起见，在本版得分超过15分以上的战友方可认领。
6.每位战友最多认领2篇。
7.作者统一署名为"丁香"。
8.文中出现的杂志名称用原文，无需翻译。
9.每认领一篇医师报商业翻译的战友须同时认领一篇当期稿件的校对工作，要在翻译帖和校对帖中分别回复认领翻译及校对。
10.编译要精炼，未特殊注明的，编译后字数最好能控制在300-800字。

Troxacitabine, Gemcitabine May Be Synergistic in Treating Pancreatic Cancer

By Martha Kerr

NEW YORK (Reuters Health) Jul 26 - Preliminary experimental studies in cell lines and in a mouse model of human pancreatic cancer show that gemcitabine and troxacitabine are "more than additive" and appear safe, investigators report in BMC Cancer published online July 3rd.

Dr. Vijaya L. Damaraju of the University of Alberta, Edmonton, Canada, and colleagues exposed four different human pancreatic adenocarcinoma cell lines to troxacitabine (Troxatyl; Thallion Pharmaceuticals) and gemcitabine (Gemzar; Eli Lilly), alone or in combination for 72 hours. Using electronic particle counting, the researchers measured the effects of the various drug treatments on cell growth.

Synergy was observed in all four cell-lines at multiple drug concentrations, resulting in a 50% reduction of cell growth, the investigators report.

In vivo studies of monotherapy or combination therapy were conducted in nude mice with established human pancreatic tumors. The results "indicated that both drugs were more than additive at well-tolerated doses and schedule," the researchers report.

"The biological basis for this synergy is unclear as we did not observe changes in apoptosis, DNA repair, troxacitabine incorporation into DNA or troxacitabine metabolism in the presence of gemcitabine," Dr. Damaraju and colleagues comment.

Co-investigator Dr. Henrietta Gourdeau of Thallion Pharmaceuticals pointed out in comments to Reuters Health, "The standard of care for the treatment of advanced pancreatic cancer is gemcitabine since 1996. It provides clinical benefit response of 22% and survival of 5.65 months (18% for 1 year survival)."

Dr. Gourdeau also noted that "troxacitabine was evaluated in a phase II trial in advanced pancreatic cancer and showed that median survival was 5.6 months (19% for 1 year survival). This is comparable to gemcitabine single agent. Since both agents can be administered at their effective doses, the fact that they are synergistic in animal models warrants that this combination be evaluated in a phase III clinical trial.

BMC Cancer 2007;7.

邀请讨论

搜索

2007-08-08 09:19 浏览 : 25848 回复 : 27

投票
收藏 25
打赏
引用
分享
- 微信扫一扫
- 新浪微博
- 丁香客
- 复制网址
举报
- 广告宣传推广
- 政治敏感、违法虚假信息
- 恶意灌水、重复发帖
- 违规侵权、站友争执
- 附件异常、链接失效
- 其他

riset 编辑于 2011-12-28 00:00

• 到底什么时间公布2020规培结业国家线??

qcywh2000

屏蔽用户

2楼

本人认领此文. 如在48小时内未能提交译文, 其他战友自由认领.

2007-08-08 09:51

投票
收藏
打赏
引用
分享
- 微信扫一扫
- 新浪微博
- 丁香客
- 复制网址
举报
- 广告宣传推广
- 政治敏感、违法虚假信息
- 恶意灌水、重复发帖
- 违规侵权、站友争执
- 附件异常、链接失效
- 其他

• 男性63岁，咳嗽、发热10天，胸部CT示右肺炎，猜病原体

huangglen

丁香园准中级站友

3楼

认领校对

2007-08-08 11:14

投票
收藏
打赏
引用
分享
- 微信扫一扫
- 新浪微博
- 丁香客
- 复制网址
举报
- 广告宣传推广
- 政治敏感、违法虚假信息
- 恶意灌水、重复发帖
- 违规侵权、站友争执
- 附件异常、链接失效
- 其他

• 到底什么时间公布2020规培结业国家线??

qcywh2000

屏蔽用户

+1 积分
4楼

蓝字处有疑问，请指正。谢谢先。

Troxacitabine, Gemcitabine May Be Synergistic in Treating Pancreatic Cancer
治疗胰腺癌：曲沙他滨加吉西他滨时有协同作用

NEW YORK (Reuters Health) Jul 26 - Preliminary experimental studies in cell lines and in a mouse model of human pancreatic cancer show that gemcitabine and troxacitabine are "more than additive" and appear safe, investigators report in BMC Cancer published online July 3rd.
纽约（路透社健康新闻）7月26日报道，细胞株及人胰腺癌小鼠模型的初期实验结果表明，曲沙他滨及吉西他滨联合应用安全且作用大于二者之和（BMC Cancer，七月三日网络版）。

Dr. Vijaya L. Damaraju of the University of Alberta, Edmonton, Canada, and colleagues exposed four different human pancreatic adenocarcinoma cell lines to troxacitabine (Troxatyl; Thallion Pharmaceuticals) and gemcitabine (Gemzar; Eli Lilly), alone or in combination for 72 hours. Using electronic particle counting, the researchers measured the effects of the various drug treatments on cell growth.
,加拿大埃德蒙顿阿尔伯塔大学Vijaya L. Damaraju博士及其同事，分别以曲沙他滨(商品名troxatyl，Thallion制药)、吉西他滨 (商品名健择，礼来药厂)单剂或二者联合处理四种不同的人胰腺癌细胞株，72个小时后应用电子颗粒计数仪测量各种给药方法对细胞生长的影响。

Synergy was observed in all four cell-lines at multiple drug concentrations, resulting in a 50% reduction of cell growth, the investigators report.
研究人员报告，在不同药物浓度时，所有四个细胞株均观察到协同效应，细胞生长抑制50%。

In vivo studies of monotherapy or combination therapy were conducted in nude mice with established human pancreatic tumors. The results "indicated that both drugs were more than additive at well-tolerated doses and schedule," the researchers report.
研究人员利用人胰腺癌裸小鼠模型进行了体内实验，单药或联合用药结果提示，在合适耐受剂量和用药方案下，联合用药效果超过两种药物相加作用。

"The biological basis for this synergy is unclear as we did not observe changes in apoptosis, DNA repair, troxacitabine incorporation into DNA or troxacitabine metabolism in the presence of gemcitabine," Dr. Damaraju and colleagues comment.
Damaraju博士及其同事称，“这种协同作用的生物学基础还不清楚，我们没有观察到吉西他滨存在情况下细胞凋亡、DNA修复、曲沙他滨整合入DNA或曲沙他滨代谢等方面发生变化。”

Co-investigator Dr. Henrietta Gourdeau of Thallion Pharmaceuticals pointed out in comments to Reuters Health, "The standard of care for the treatment of advanced pancreatic cancer is gemcitabine since 1996. It provides clinical benefit response of 22% and survival of 5.65 months (18% for 1 year survival)."
共同研究者、Thallion制药的Henrietta Gourdeau博士指出，" 1996年，吉西他滨获准成为治疗晚期胰腺癌的一线药物，患者临床获益率22%，生存期5.65个月(1年生存率18%)。"

Dr. Gourdeau also noted that "troxacitabine was evaluated in a phase II trial in advanced pancreatic cancer and showed that median survival was 5.6 months (19% for 1 year survival). This is comparable to gemcitabine single agent. Since both agents can be administered at their effective doses, the fact that they are synergistic in animal models warrants that this combination be evaluated in a phase III clinical trial.
Gourdeau博士还指出，曲沙他滨治疗晚期胰腺癌的三期临床试验结果表明，患者中位生存时间为5.6个月(1年生存率为19%)。这与吉西他滨单剂效果等同。因为两种药物均可投用各自有效剂量，它们在动物模型中表现出的协同作用，也为三期临床试验提供了依据。
BMC Cancer 2007;7.
____________________________________________________________________

编译 491字

胰腺癌治疗：曲沙他滨与吉西他滨的协同作用
细胞株及人胰腺癌小鼠模型的初期实验结果表明，联合应用曲沙他滨(商品名troxatyl，Thallion制药)及吉西他滨(商品名健择，礼来药厂)安全且有协同作用（BMC Cancer 2007;7.）。
加拿大阿尔伯塔大学Vijaya L. Damaraju博士及其同事，分别以曲沙他滨、吉西他滨单剂或二药联合处理四种不同的人胰腺癌细胞株，72个小时后应用电子颗粒计数仪测量三种给药方法对细胞生长的影响。结果表明，不同药物浓度时，所有细胞株均观察到协同效应，细胞生长抑制50%。
人胰腺癌裸小鼠模型体内实验单药或联合用药结果提示，在合适耐受剂量和用药方案下，联合用药效果超过两种药物相加作用。
Damaraju博士称，这种协同作用的生物学基础还不清楚，未观察到吉西他滨存在情况下细胞凋亡、DNA修复、曲沙他滨整合入DNA或曲沙他滨代谢等方面发生变化。
1996年，吉西他滨获准成为治疗晚期胰腺癌的一线药物，患者临床获益率22%，生存期5.65个月(1年生存率18%)。曲沙他滨治疗晚期胰腺癌的二期临床期试验结果表明，患者中位生存时间为5.6个月(1年生存率为19%)，这与吉西他滨单剂效果等同。
因为两种药物联合应用时均可投用各自有效剂量，它们在动物模型中表现出的协同作用，也为三期临床试验提供了依据。

2007-08-08 16:24

投票
收藏 9
打赏
引用
分享
- 微信扫一扫
- 新浪微博
- 丁香客
- 复制网址
举报
- 广告宣传推广
- 政治敏感、违法虚假信息
- 恶意灌水、重复发帖
- 违规侵权、站友争执
- 附件异常、链接失效
- 其他

riset 编辑于 2012-01-17 18:23

• 2021考研打卡签到（倒计时 98 天）

科技动态

【商业翻译—医师报约稿】Troxacitabine, Gemcitabine May Be Synergistic ...

提示

丁香园旗下网站

关于丁香园

官方链接

科技动态

分享到：

微信扫一扫

【商业翻译—医师报约稿】Troxacitabine, Gemcitabine May Be Synergistic ...

微信扫一扫

微信扫一扫

微信扫一扫

微信扫一扫

提示

丁香园旗下网站

关于丁香园

官方链接